

## PAP Selected References

1. Rosen SG, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. *New England Journal of Medicine* 1958; 258:1123-42.
2. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. *Science* 1994; 264:713-6.
3. Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. *Immunity* 1995; 2:211-22.
4. Ikegami M, Ueda T, Hull W, et al. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. *Am J Physiol* 1996; 270:L650-8.
5. LeVine AM, Reed JA, Kurak KE, Cianciolo E, Whitsett JA. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. *J Clin Invest* 1999; 103:563-9.
6. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. *J Exp Med* 1999; 190:875-80.
7. Shibata Y, Berclaz P-Y, Chroneos Z, Yoshida H, Whitsett JA, Trapnell BC. GM-CSF Regulates Alveolar Macrophage Differentiation and Innate Immunity in the Lung Through PU.1. *Immunity* 2001; 15:557-567.
8. Ben-Dov I, Kishinevski Y, Roznman J, et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. *Isr Med Assoc J* 1999; 1:75-8.
9. deMello DE, Lin Z. Pulmonary alveolar proteinosis: a review. *Pediatr Pathol Mol Med* 2001; 20:413-32.
10. Goldstein LS, Kavuru MS, Curtis-McCarthy P, Christie HA, Farver C, Stoller JK. Pulmonary alveolar proteinosis: clinical features and outcomes. *Chest* 1998; 114:1357-62.
11. Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. *Mayo Clin Proc* 1987; 62:499-518.
12. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. *Am J Respir Crit Care Med* 2002; 166:215-35.
13. Asamoto H, Kitaichi M, Nishimura K, Itoh H, Izumi T. [Primary pulmonary alveolar proteinosis--clinical observation of 68 patients in Japan]. *Nihon Kyobu Shikkan Gakkai Zasshi* 1995; 33:835-45.
14. Bedrossian CW, Luna MA, Conklin RH, Miller WC. Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. *Hum Pathol* 1980; 11:527-35.
15. Andriole MT, Ballas M, Wilson GL. The Association of Nocardiosis and Pulmonary Alveolar Proteinosis: A Case Study. *Ann Intern Med* 1963; 60:266-275.
16. Supena R, Karlin D, Strate R, Cramer PG. Pulmonary alveolar proteinosis and Nocardia brain abscess. Report of a case. *Arch Neurol* 1974; 30:266-8.
17. Oerlemans WG, Jansen EN, Prevo RL, Eijssvogel MM. Primary cerebellar

- nocardiosis and alveolar proteinosis. *Acta Neurol Scand* 1998; 97:138-41.
18. Walker DA, McMahan SM. Pulmonary alveolar proteinosis complicated by cerebral abscess: report of a case. *J Am Osteopath Assoc* 1986; 86:447-50.
  19. Ramirez-Rivera J, Schultz RB, Dutton RE. Pulmonary Alveolar Proteinosis: A New Technique and Rational for Treatment. *Archives of Internal Medicine* 1963; 112:173-185.
  20. Ramirez-Rivera J, Nyka W, McLaughlin J. Pulmonary Alveolar Proteinosis: Diagnostic Technics adn Observations. *N Engl J Med* 1963; 268:165-71.
  21. Wasserman K, Masson GR. Pulmonary Alveolar Proteinosis. In: Murray JF, Nadel JA, eds. *Textbook of Respiratory Medicine*. Philadelphia: Saunders, 1994:1933-1946.
  22. Du Bois RM, McAllister WA, Branthwaite MA. Alveolar proteinosis: diagnosis and treatment over a 10-year period. *Thorax* 1983; 38:360-3.
  23. Kariman K, Kylstra JA, Spock A. Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. *Lung* 1984; 162:223-31.
  24. Hoffman RM, Dauber JH, Rogers RM. Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis. *Am Rev Respir Dis* 1989; 139:1030-2.
  25. Bury T, Corhay JL, Saint-Remy P, Radermecker M. [Alveolar proteinosis: restoration of the function of the alveolar macrophages after therapeutic lavage]. *Rev Mal Respir* 1989; 6:373-5.
  26. Cheng SL, Chang HT, Lau HP, Lee LN, Yang PC. Pulmonary alveolar proteinosis: treatment by bronchofiberscopic lobar lavage. *Chest* 2002; 122:1480-5.
  27. Costello JF, Moriarty DC, Branthwaite MA, Turner-Warwick M, Corrin B. Diagnosis and management of alveolar proteinosis: the role of electron microscopy. *Thorax* 1975; 30:121-32.
  28. Davidson JM, Macleod WM. Pulmonary alveolar proteinosis. *Br J Dis Chest* 1969; 63:13-28.
  29. Singh G, Katyal SL, Bedrossian CW, Rogers RM. Pulmonary alveolar proteinosis. Staining for surfactant apoprotein in alveolar proteinosis and in conditions simulating it. *Chest* 1983; 83:82-6.
  30. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T. Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. *Chest* 1993; 103:496-9.
  31. McClenahan JB. Pulmonary alveolar proteinosis. *Arch Intern Med* 1974; 133:284-7.
  32. Trapnell BC, Whitsett JA. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol* 2002; 64:775-802.
  33. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. *Proc Natl Acad Sci U S A* 1994; 91:5592-6.
  34. Robb L, Drinkwater CC, Metcalf D, et al. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. *Proc Natl Acad Sci U S A* 1995; 92:9565-9.
  35. Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC. GM-CSF, via PU.1, regulates alveolar macrophage FcγR-mediated

- phagocytosis and the IL-18/IFN-gamma - mediated molecular connection between innate and adaptive immunity in the lung. *Blood* 2002; 100:4193-200.
36. Berclaz PY, Zsengeller Z, Shibata Y, et al. Endocytic Internalization of Adenovirus, Nonspecific Phagocytosis, and Cytoskeletal Organization Are Coordinately Regulated in Alveolar Macrophages by GM-CSF and PU.1. *J Immunol* 2002; 169:6332-42.
  37. Paine R, 3rd, Morris SB, Jin H, et al. Impaired functional activity of alveolar macrophages from GM-CSF- deficient mice. *Am J Physiol Lung Cell Mol Physiol* 2001; 281:L1210-8.
  38. Paine R, 3rd, Preston AM, Wilcoxon S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to *Pneumocystis carinii* pneumonia in mice. *J Immunol* 2000; 164:2602-9.
  39. Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF- deficient mice. *Am J Physiol* 1999; 276:L556-63.
  40. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice [see comments]. *J Clin Invest* 1996; 97:649-55.
  41. Zsengeller ZK, Reed JA, Bachurski CJ, et al. Adenovirus-mediated granulocyte-macrophage colony-stimulating factor improves lung pathology of pulmonary alveolar proteinosis in granulocyte-macrophage colony-stimulating factor-deficient mice. *Hum Gene Ther* 1998; 9:2101-9.
  42. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene [see comments]. *Cell* 1990; 61:113-24.
  43. Hromas R, Orazi A, Neiman RS, et al. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. *Blood* 1993; 82:2998-3004.
  44. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 1994; 265:1573-7.
  45. Celada A, Borrás FE, Soler C, et al. The transcription factor PU.1 is involved in macrophage proliferation. *J Exp Med* 1996; 184:61-9.
  46. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. *Embo J* 1996; 15:5647-58.
  47. Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. *Blood* 1998; 91:3702-10.
  48. Lloberas J, Soler C, Celada A. The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages. *Immunol Today* 1999; 20:184-189.
  49. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. *Science* 2000; 288:1439-41.
  50. Seymour JF, Dunn AR, Vincent JM, Presneill JJ, Pain MC. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. *N Engl J Med* 1996; 335:1924-5.
  51. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. *Am J Respir Crit Care Med* 2001; 163:524-31.

52. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. *Am J Respir Crit Care Med* 2000; 161:1143-8.
53. Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. *Am J Respir Crit Care Med* 2000; 161:1294-9.
54. Bewig B, Wang XD, Kirsten D, Dalhoff K, Schafer H. GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis. *Eur Respir J* 2000; 15:350-7.
55. Dirksen U, Hattenhorst U, Schneider P, et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. *Blood* 1998; 92:1097-103.
56. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. *FEBS Lett* 1999; 442:246-50.
57. Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis [In Process Citation]. *Am J Respir Crit Care Med* 2000; 162:658-62.
58. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. *Am J Respir Cell Mol Biol* 2002; 27:481-6.
59. Mazzone PJ, Sullivan EJ, Piccin R, Stoller JK, Thomassen JJ, Kavuru MS. Granulocyte Macrophage-Colony Stimulating Factor Therapy For Pulmonary Alveolar Proteinosis. *Am Rev Respir Dis* 2000; 161:A888.
60. Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. *Thorax* 2002; 57:277-80.
61. Tazawa R, Ishimoto O, Ohta H, et al. Granulocyte-Macrophage Colony Stimulating Factor Inhalation Therapy As a Treatment for Pulmonary Alveolar Proteinosis. Submitted.
62. Trapnell BC, Whitsett JA, and Nakata K. Mechanism of Disease: Pulmonary Alveolar Proteinosis. *New England Journal of Medicine*. 349:2527-39; 2003.
63. Uchida K, Nakata K, Trapnell BC, et al. High Affinity Autoantibodies Specifically Eliminate Granulocyte-Macrophage Colony Stimulating Factor Activity In The Lungs Of Patients With Idiopathic Pulmonary Alveolar Proteinosis. *Blood*. 103: 1089-98; 2004.